Jia Hao Yeo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jia Hao Yeo has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Lay-Hoon Kwa
Department of Pharmacy, Singapore General Hospital, Singapore
7 shared publications - Elizabeth J. New
School of Chemistry, The University of Sydney, NSW 2006, Australia
5 shared publications Yang Zhong
Division of Pharmacy, Singapore General Hospital, Singapore, Singapore
4 shared publicationsNasren Begam
3 shared publicationsShuhua Thong
Division of Pharmacy, Singapore General Hospital, Singapore; SingHealth Duke-NUS Academic Clinical Programme (Pathology), Singapore
3 shared publicationsZhanlong Wang
School of Chemistry The University of Sydney NSW 2006 Australia)
3 shared publications
Latest Publications
- 12 February 2026
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 67 (5) , 107739
Assessing carbonylation in Pseudomonas aeruginosa clinical isolates infected by bacteriophages using flow cytometry
- 12 February 2026
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 67 (5) , 107739
Assessing carbonylation in Pseudomonas aeruginosa clinical isolates infected by bacteriophages using flow cytometry
- Top Cited PapersOpen Access
- 9 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Timely bespoke phage-antibiotic combination to treat refractory Pseudomonas aeruginosa mediastinitis and vascular graft infection
Biofilm-related vascular graft infections (VGIs) pose major therapeutic challenges due to persistent, antibiotic-resistant bacteria often residing in retained grafts. Phage therapy offers a promising alternative treatment strategy against biofilm-associated infections, though its use remains mostly ad hoc and typically considered a last-resort intervention. We report here the treatment of a refractory, fluoroquinolone non-susceptible Pseudomonas aeruginosa VGI using a systematically planned and synergistic phage-antibiotic combination approach. Adjunctive phage therapy led to radiological improvement, as seen by reduced 18F-FDG PET/CT tracer uptake around the graft. The patient was transitioned to oral fluoroquinolone suppression therapy with no recurrence of bacteremia to-date, after a year. Our workflow led to the selection of phages that sensitized Pseudomonas aeruginosa to killing by levofloxacin and piperacillin-tazobactam. We established that this phage-driven antibiotic sensitization was due to the ability of our phages to use the MexAB-OprM efflux pump as a receptor. We also showed that our phages had potent anti-biofilm activity. We advocate a systematic, multi-pronged management strategy for refractory VGIs, including early therapeutic drug monitoring (TDM), in vitro antibiotic combination testing (iACT), and timely adjunctive phage therapy. This case illustrates the utility of individualized, strategic approaches and highlights adjunctive phage therapy’s potential in treating complex biofilm-related infections.
- 9 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Top Cited PapersOpen AccessTimely bespoke phage-antibiotic combination to treat refractory Pseudomonas aeruginosa mediastinitis and vascular graft infection
Biofilm-related vascular graft infections (VGIs) pose major therapeutic challenges due to persistent, antibiotic-resistant bacteria often residing in retained grafts. Phage therapy offers a promising alternative treatment strategy against biofilm-associated infections, though its use remains mostly ad hoc and typically considered a last-resort intervention. We report here the treatment of a refractory, fluoroquinolone non-susceptible Pseudomonas aeruginosa VGI using a systematically planned and synergistic phage-antibiotic combination approach. Adjunctive phage therapy led to radiological improvement, as seen by reduced 18F-FDG PET/CT tracer uptake around the graft. The patient was transitioned to oral fluoroquinolone suppression therapy with no recurrence of bacteremia to-date, after a year. Our workflow led to the selection of phages that sensitized Pseudomonas aeruginosa to killing by levofloxacin and piperacillin-tazobactam. We established that this phage-driven antibiotic sensitization was due to the ability of our phages to use the MexAB-OprM efflux pump as a receptor. We also showed that our phages had potent anti-biofilm activity. We advocate a systematic, multi-pronged management strategy for refractory VGIs, including early therapeutic drug monitoring (TDM), in vitro antibiotic combination testing (iACT), and timely adjunctive phage therapy. This case illustrates the utility of individualized, strategic approaches and highlights adjunctive phage therapy’s potential in treating complex biofilm-related infections.
- Open Access
Assessing bactericidal dynamics of persister-manifested clinical isolates in the presence of macrophages and antibiotics
Antibiotics are often depicted to reduce bacterial load for immuno-clearance. Recurring infections can be caused by bacteria persisters that survived antibiotic treatment. It is unclear how the host immunity manages infection by persister-manifested strains during antibiotic treatment. Differentiated THP-1 macrophages were exposed to persister-manifested clinical isolates at various multiplicities-of-infection (MOI), in the presence or absence of meropenem. Across all MOIs, meropenem did not greatly reduce the intracellular bacterial load nor eradicate all extra-macrophagic non-persister bacteria. Bactericidal effects on extracellular bacteria vary for each strain after meropenem treatment in mildly infected macrophages. In severely infected macrophages, extra-macrophagic bacteria of all isolates decreases in numbers followed by a bacteriostatic-like effect. Our findings contradict the common notion that antibiotics generally reduce the bacterial load for immune clearance. Our study suggests that the bactericidal effects of meropenem differs with host presence and can be dependent on bacterial load.
Open AccessAssessing bactericidal dynamics of persister-manifested clinical isolates in the presence of macrophages and antibiotics
Antibiotics are often depicted to reduce bacterial load for immuno-clearance. Recurring infections can be caused by bacteria persisters that survived antibiotic treatment. It is unclear how the host immunity manages infection by persister-manifested strains during antibiotic treatment. Differentiated THP-1 macrophages were exposed to persister-manifested clinical isolates at various multiplicities-of-infection (MOI), in the presence or absence of meropenem. Across all MOIs, meropenem did not greatly reduce the intracellular bacterial load nor eradicate all extra-macrophagic non-persister bacteria. Bactericidal effects on extracellular bacteria vary for each strain after meropenem treatment in mildly infected macrophages. In severely infected macrophages, extra-macrophagic bacteria of all isolates decreases in numbers followed by a bacteriostatic-like effect. Our findings contradict the common notion that antibiotics generally reduce the bacterial load for immune clearance. Our study suggests that the bactericidal effects of meropenem differs with host presence and can be dependent on bacterial load.
- Open Access
- 4 September 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (9) , e0331217
Determining minimal inhibitory concentrations and antibiotic susceptibility for Enterobacterales by flow cytometry using reactive oxygen species as a marker
Early appropriate antibiotic treatment is vital in reducing patient mortality. However, current antimicrobial susceptibility testing (AST) requires 16–24 hours of incubation, delaying appropriate antibiotic treatment. Flow cytometry (FCM) is a rapid method in assessing fluorescence (such as fluorophores for ROS) at single-cell resolution. Reactive oxygen species (ROS) are oxygen-containing molecules, which are inducible by antibiotics and potentially bactericidal. We asked if FCM measurements of ROS in antibiotic-treated bacteria could be used in determining antibiotic MIC as an alternative to conventional AST. This study aims to develop and evaluate the feasibility of a FCM assay to determine antibiotic susceptibility accurately with a short turn-around time. MICs of amikacins, aztreonams, cephalosporins (with or without a lactamase inhibitor), carbapenems, levofloxacin, polymyxin B, trimethoprim/sulfamethoxazole, and tigecycline were determined for six clinical carbapenem-resistant Enterobacterales isolates using conventional microbroth dilution assays and using FCM assessments in parallel. Accurate MICs determined using FCM is defined as MICs falling within 2-fold dilutions of the conventional microbroth dilution AST assay. MIC determination via ROS measurements were mostly accurate for carbapenems (22/24; 91.7% accuracy) and trimethoprim/sulfamethoxazole (5/6; 83.3% accuracy). In contrary, ROS levels were less accurate in determining MICs for amikacin (4/6; 66.7% accuracy), aztreonam (4/6; 66.7% accuracy), cephalosporins only (5/12; 41.6% accuracy), cephalosporin with lactamase inhibitor (11/18; 61.1% accuracy), polymyxin-B (2/6; 33.3% accuracy), levofloxacin (1/6; 16.7% accuracy), and tigecycline (2/6; 33.3% accuracy). These data support that ROS assessments using FCM is suitable for accurately determining MICs for carbapenems in Enterobacterales. Further optimisation and validation of this FCM assay with additional bacteria strains with varying antibiotic susceptibilities are warranted. Future studies include assessing other organisms and antibiotic pairs.
- 4 September 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (9) , e0331217
Open AccessDetermining minimal inhibitory concentrations and antibiotic susceptibility for Enterobacterales by flow cytometry using reactive oxygen species as a marker
Early appropriate antibiotic treatment is vital in reducing patient mortality. However, current antimicrobial susceptibility testing (AST) requires 16–24 hours of incubation, delaying appropriate antibiotic treatment. Flow cytometry (FCM) is a rapid method in assessing fluorescence (such as fluorophores for ROS) at single-cell resolution. Reactive oxygen species (ROS) are oxygen-containing molecules, which are inducible by antibiotics and potentially bactericidal. We asked if FCM measurements of ROS in antibiotic-treated bacteria could be used in determining antibiotic MIC as an alternative to conventional AST. This study aims to develop and evaluate the feasibility of a FCM assay to determine antibiotic susceptibility accurately with a short turn-around time. MICs of amikacins, aztreonams, cephalosporins (with or without a lactamase inhibitor), carbapenems, levofloxacin, polymyxin B, trimethoprim/sulfamethoxazole, and tigecycline were determined for six clinical carbapenem-resistant Enterobacterales isolates using conventional microbroth dilution assays and using FCM assessments in parallel. Accurate MICs determined using FCM is defined as MICs falling within 2-fold dilutions of the conventional microbroth dilution AST assay. MIC determination via ROS measurements were mostly accurate for carbapenems (22/24; 91.7% accuracy) and trimethoprim/sulfamethoxazole (5/6; 83.3% accuracy). In contrary, ROS levels were less accurate in determining MICs for amikacin (4/6; 66.7% accuracy), aztreonam (4/6; 66.7% accuracy), cephalosporins only (5/12; 41.6% accuracy), cephalosporin with lactamase inhibitor (11/18; 61.1% accuracy), polymyxin-B (2/6; 33.3% accuracy), levofloxacin (1/6; 16.7% accuracy), and tigecycline (2/6; 33.3% accuracy). These data support that ROS assessments using FCM is suitable for accurately determining MICs for carbapenems in Enterobacterales. Further optimisation and validation of this FCM assay with additional bacteria strains with varying antibiotic susceptibilities are warranted. Future studies include assessing other organisms and antibiotic pairs.
- Open Access
- 22 July 2025
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 44, 340-346
Comparative in vitro activities of eravacycline and tigecycline against carbapenem-resistant Acinetobacter baumannii: Insights from whole genome sequencing analysis
- 22 July 2025
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 44, 340-346
Open AccessComparative in vitro activities of eravacycline and tigecycline against carbapenem-resistant Acinetobacter baumannii: Insights from whole genome sequencing analysis
- Open Access
- 24 June 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (6) , e0305939
Can flow cytometric measurements of reactive oxygen species levels determine minimal inhibitory concentrations and antibiotic susceptibility testing for Acinetobacter baumannii?
Current antimicrobial susceptibility testing (AST) requires 16–24 hours, delaying initiation of appropriate antibiotics. Hence, there is a need for rapid AST. This study aims to develop and evaluate the feasibility of a rapid flow cytometric AST assay to determine minimum inhibitory concentration (MIC) for carbapenem-resistant Acinetobacter baumannii (CRAB). Antibiotic exposure causes increased intracellular reactive oxygen species (ROS) in bacteria. We hypothesized that ROS can be used as a marker to determine MIC. We assessed three CRAB clinical isolates across fifteen antibiotics at various concentrations in a customized 96-well microtiter plate. The antibiotics assessed include amikacin, beta-lactams (ampicillin/sulbactam, aztreonam, cefepime, ceftolozane/tazobactam, doripenem, imipenem, meropenem, and piperacillin/tazobactam), levofloxacin, polymyxin B, rifampicin, trimethoprim/sulfamethoxazole, and tetracyclines (tigecycline and minocycline). These clinical CRAB isolates were assessed for ROS after antibiotic treatment. Increased ROS levels indicated by increased RedoxSensorTM Green (RSG) fluorescence intensity was assessed using flow cytometry (FCM). MIC was set as the lowest antibiotic concentration that gives a ≥1.5-fold increase in mode RSG fluorescence intensity (MICRSG). Accuracy of MICRSG was determined by comparing against microtiter broth dilution method performed under CLSI guidelines. ROS was deemed accurate in determining the MICs for β-lactams (83.3% accuracy) and trimethoprim/sulfamethoxazole (100% accuracy). In contrast, ROS is less accurate in determining MICs for levofloxacin (33.3% accuracy), rifampicin (0% accuracy), amikacin (33.3% accuracy), and tetracyclines (33.3% accuracy). Collectively, this study described an FCM-AST assay to determine antibiotic susceptibility of CRAB isolates within 5 hours, reducing turnaround time up to 19 hours.
- 24 June 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (6) , e0305939
Open AccessCan flow cytometric measurements of reactive oxygen species levels determine minimal inhibitory concentrations and antibiotic susceptibility testing for Acinetobacter baumannii?
Current antimicrobial susceptibility testing (AST) requires 16–24 hours, delaying initiation of appropriate antibiotics. Hence, there is a need for rapid AST. This study aims to develop and evaluate the feasibility of a rapid flow cytometric AST assay to determine minimum inhibitory concentration (MIC) for carbapenem-resistant Acinetobacter baumannii (CRAB). Antibiotic exposure causes increased intracellular reactive oxygen species (ROS) in bacteria. We hypothesized that ROS can be used as a marker to determine MIC. We assessed three CRAB clinical isolates across fifteen antibiotics at various concentrations in a customized 96-well microtiter plate. The antibiotics assessed include amikacin, beta-lactams (ampicillin/sulbactam, aztreonam, cefepime, ceftolozane/tazobactam, doripenem, imipenem, meropenem, and piperacillin/tazobactam), levofloxacin, polymyxin B, rifampicin, trimethoprim/sulfamethoxazole, and tetracyclines (tigecycline and minocycline). These clinical CRAB isolates were assessed for ROS after antibiotic treatment. Increased ROS levels indicated by increased RedoxSensorTM Green (RSG) fluorescence intensity was assessed using flow cytometry (FCM). MIC was set as the lowest antibiotic concentration that gives a ≥1.5-fold increase in mode RSG fluorescence intensity (MICRSG). Accuracy of MICRSG was determined by comparing against microtiter broth dilution method performed under CLSI guidelines. ROS was deemed accurate in determining the MICs for β-lactams (83.3% accuracy) and trimethoprim/sulfamethoxazole (100% accuracy). In contrast, ROS is less accurate in determining MICs for levofloxacin (33.3% accuracy), rifampicin (0% accuracy), amikacin (33.3% accuracy), and tetracyclines (33.3% accuracy). Collectively, this study described an FCM-AST assay to determine antibiotic susceptibility of CRAB isolates within 5 hours, reducing turnaround time up to 19 hours.
- Open Access
- 12 May 2024
- Published by MDPI AG in Microorganisms
- Vol. 12 (5) , 972
Ironing out Persisters? Revisiting the Iron Chelation Strategy to Target Planktonic Bacterial Persisters Harboured in Carbapenem-Resistant Escherichia coli
Antibiotic resistance is a global health crisis. Notably, carbapenem-resistant Enterobacterales (CRE) pose a significant clinical challenge due to the limited effective treatment options. This problem is exacerbated by persisters that develop upon antibiotic exposure. Bacteria persisters can tolerate high antibiotic doses and can cause recalcitrant infections, potentially developing further antibiotic resistance. Iron is a critical micronutrient for survival. We aimed to evaluate the utility of iron chelators, alone and in combination with antibiotics, in managing persisters. We hypothesized that iron chelators eradicate CRE persisters in vitro, when administered in combination with antibiotics. Our screening revealed three clinical isolates with bacteria persisters that resuscitated upon antibiotic removal. These isolates were treated with both meropenem and an iron chelator (deferoxamine mesylate, deferiprone or dexrazoxane) over 24 h. Against our hypothesis, bacteria persisters survived and resuscitated upon withdrawing both the antibiotic and iron chelator. Pursuing our aim, we next hypothesized that iron chelation is feasible as a post-antibiotic treatment in managing and suppressing persisters’ resuscitation. We exposed bacteria persisters to an iron chelator without antibiotics. Flow cytometric assessments revealed that iron chelators are inconsistent in suppressing persister resuscitation. Collectively, these results suggest that the iron chelation strategy may not be useful as an antibiotic adjunct to target planktonic bacteria persisters.
- 12 May 2024
- Published by MDPI AG in Microorganisms
- Vol. 12 (5) , 972
Open AccessIroning out Persisters? Revisiting the Iron Chelation Strategy to Target Planktonic Bacterial Persisters Harboured in Carbapenem-Resistant Escherichia coli
Antibiotic resistance is a global health crisis. Notably, carbapenem-resistant Enterobacterales (CRE) pose a significant clinical challenge due to the limited effective treatment options. This problem is exacerbated by persisters that develop upon antibiotic exposure. Bacteria persisters can tolerate high antibiotic doses and can cause recalcitrant infections, potentially developing further antibiotic resistance. Iron is a critical micronutrient for survival. We aimed to evaluate the utility of iron chelators, alone and in combination with antibiotics, in managing persisters. We hypothesized that iron chelators eradicate CRE persisters in vitro, when administered in combination with antibiotics. Our screening revealed three clinical isolates with bacteria persisters that resuscitated upon antibiotic removal. These isolates were treated with both meropenem and an iron chelator (deferoxamine mesylate, deferiprone or dexrazoxane) over 24 h. Against our hypothesis, bacteria persisters survived and resuscitated upon withdrawing both the antibiotic and iron chelator. Pursuing our aim, we next hypothesized that iron chelation is feasible as a post-antibiotic treatment in managing and suppressing persisters’ resuscitation. We exposed bacteria persisters to an iron chelator without antibiotics. Flow cytometric assessments revealed that iron chelators are inconsistent in suppressing persister resuscitation. Collectively, these results suggest that the iron chelation strategy may not be useful as an antibiotic adjunct to target planktonic bacteria persisters.
- Open Access
- 29 March 2022
- Published by CSIRO Publishing in Australian Journal of Chemistry
- Vol. 75 (9) , 716-724
New boron-based coumarin fluorophores for bioimaging applications†
The synthesis and characterisation of five new boron-based coumarin fluorophores are reported, with key structural variations involving the linker at the C3-position (hydrazone or imine) of the 7-(diethylamino)-coumarin (7DEAC) core and the terminal boron moiety (i.e. boronic acid or closo-1,2-carborane). All the coumarin derivatives were found to display significant bathochromic shifts relative to the parent 7DEAC, with conjugate ICCb displaying the greatest overall shift. Confocal microscopy studies with A549 lung cancer cells showed clear differences in the observed intra-cellular distributions of the fluorophores. The polar boronic acid species (HCoBA, HCmBA and HCpBA) were found to localise in the endoplasmic reticulum. In contrast, the lipophilic closo-1,2-carborane derivatives (HCCb and ICCb) were found to localise within lipid droplets (LDs), showcasing the future potential for these probes to be utilised as stains for LD observations by means of confocal microscopy.
- 29 March 2022
- Published by CSIRO Publishing in Australian Journal of Chemistry
- Vol. 75 (9) , 716-724
Open AccessNew boron-based coumarin fluorophores for bioimaging applications†
The synthesis and characterisation of five new boron-based coumarin fluorophores are reported, with key structural variations involving the linker at the C3-position (hydrazone or imine) of the 7-(diethylamino)-coumarin (7DEAC) core and the terminal boron moiety (i.e. boronic acid or closo-1,2-carborane). All the coumarin derivatives were found to display significant bathochromic shifts relative to the parent 7DEAC, with conjugate ICCb displaying the greatest overall shift. Confocal microscopy studies with A549 lung cancer cells showed clear differences in the observed intra-cellular distributions of the fluorophores. The polar boronic acid species (HCoBA, HCmBA and HCpBA) were found to localise in the endoplasmic reticulum. In contrast, the lipophilic closo-1,2-carborane derivatives (HCCb and ICCb) were found to localise within lipid droplets (LDs), showcasing the future potential for these probes to be utilised as stains for LD observations by means of confocal microscopy.
- Open Access
- 9 April 2021
- Published by Wiley in Analysis & Sensing
- Vol. 1 (2) , 70
Front Cover: Elucidating the Roles of Fenton Reactants in Drug‐Treated Cells by Using a Selective Rhodamine‐Thiophenol Fluorogenic Sensor (2/2021)
- 9 April 2021
- Published by Wiley in Analysis & Sensing
- Vol. 1 (2) , 70
Open AccessFront Cover: Elucidating the Roles of Fenton Reactants in Drug‐Treated Cells by Using a Selective Rhodamine‐Thiophenol Fluorogenic Sensor (2/2021)